Exhibit 10.5

 

Certain information identified by bracketed asterisks ([* * *]) has been omitted
from this exhibit because it is both not material and would be competitively
harmful if publicly disclosed.

 

ASSET PURCHASE AGREEMENT

 

THIS ASSET PURCHASE AGREEMENT (this “Agreement”) dated as of May 6, 2019 (the
“Effective Date”), is entered into between ETON PHARMACEUTICALS, INC., a
Delaware corporation (“Eton”), with a place of business at 21925 W. Field
Parkway, Suite 235, Deer Park, Illinois 60010, and HARROW HEALTH, INC., a
Delaware corporation f/k/a Imprimis Pharmaceuticals, Inc. (“Harrow”), with a
place of business at 12264 El Camino Real, Suite 350, San Diego, California
92130.

 

WHEREAS, the parties entered into the Asset Purchase and License Agreement dated
as of May 9, 2017, whereby Harrow assigned certain assets related to the Product
(as defined below) to Eton (the “Original Agreement”); and

 

WHEREAS, the parties desire to terminate the Original Agreement and to transfer
certain assets related to the Product from Eton to Harrow on the terms and
conditions of this Agreement;

 

NOW, THEREFORE, in consideration of the mutual promises and covenants set forth
below and other good and valuable consideration, the receipt and sufficiency of
which is hereby acknowledged, the parties hereby agree as follows:

 

1. Definitions. For the purposes of this Agreement, the following terms shall
have the respective meanings set forth below, and grammatical variations of such
terms shall have corresponding meanings:

 

1.1 “Affiliate” means, with respect to any Person, any other Person which
directly or indirectly controls, is controlled by, or is under common control
with, such Person. A Person shall be regarded as in control of another Person if
it owns, or directly or indirectly controls, more than fifty percent (50%) of
the voting stock or other ownership interest of the other Person, or if it
directly or indirectly possesses the power to direct or cause the direction of
the management and policies of the other Person by any means whatsoever.
Notwithstanding the foregoing, for purposes of this Agreement, neither Harrow
nor Eton shall be Affiliates of the other or the other’s Affiliates.

 

1.2 “Assets” means, collectively, (a) the Technology; (b) all discoveries,
inventions, technology, compositions, formulations, samples, components,
processes, standards, methods, procedures and techniques relating thereto; (c)
all formulae, data, information, results of experimentation and testing, and
other know-how, whether or not patentable or copyrightable, relating thereto;
(d) all Regulatory Filings and Regulatory Approvals therefor or relating
thereto; and (e) all intellectual property rights and other assets relating
thereto (including without limitation the Assigned Patent Rights and Assigned
Know-How Rights).

 

 1 

 

 

1.3 “Assigned Know-How Rights” means all trade secret and other know-how rights
related to the Technology owned by Eton as of the Effective Date.

 

1.4 “Assigned Patent Rights” means, collectively, (a) all patents and patent
applications (including provisional patent applications) in any jurisdiction
that claim or cover the Technology, including those listed on Schedule 1 to
Exhibit A, together with all divisionals, continuations and
continuations-in-part that claim priority to, or common priority with, the
foregoing; (b) all patents issuing therefrom (including utility models and
design patents and certificates of invention); (c) all reissues, reexaminations,
inter partes reviews, renewals, restorations, extensions and supplementary
protection certificates of any of the foregoing patent applications or patents;
(d) all confirmation patents, registration patents or patents of addition based
on any of the foregoing patents; and (e) all foreign counterparts of any of the
foregoing, or as applicable portions thereof.

 

1.5 “Contract” or “Contracts” means any mortgage, indenture, lease, contract,
covenant, arrangement, agreement, instrument, commitment, purchase order or
license.

 

1.6 “Encumbrance” or “Encumbrances” means any encumbrance, lien, charge,
hypothecation, pledge, mortgage, adverse claim, option, preemptive right, or
other security interest of any nature, or any Contract to create any of the
foregoing entered into by Eton on or before the Effective Date.

 

1.7 “FDA” means the Food and Drug Administration of the United States, or any
successor thereto.

 

1.8 “First Commercial Sale” means, with respect to any Product, the first sale
of such Product by Harrow, its Licensees, or its or their respective Affiliates
after all applicable Regulatory Approvals (if any) have been granted by the
applicable Regulatory Authority.

 

1.9 “Knowledge of Eton” or “Eton’s Knowledge” means the actual knowledge of any
director, officer, member or employee of Eton and the knowledge such individuals
would reasonably be expected to obtain in the course of diligently performing
his or her duties for Eton and/or making a reasonable inquiry into the matters
contemplated by this Agreement.

 

1.10 “Licensee” means a Third Party to whom Harrow has granted a license,
immunity or other right under the Assigned Patent Rights to offer to sell, sell
or otherwise commercialize one or more Products, provided such license has not
expired or been terminated.

 

1.11 “Net Sales” means, with respect to any Product, the gross sales price of
such Product invoiced by Harrow, its Licensees, and its and their respective
Affiliates to customers who are not Affiliates (or are Affiliates but are the
end users of such Product), less (a) credits, allowances, discounts and rebates
to, and chargebacks from the account of, such customers; (b) freight and
insurance costs in transporting such Product to the extent separately invoiced
and included in the gross sales price; (c) cash, quantity and trade discounts,
rebates and other price reductions for such Product; (d) sales, use, value-added
and other direct taxes for such Product to the extent separately invoiced and
included in the gross sales price; (e) customs duties, tariffs, surcharges and
other governmental charges incurred in exporting or importing such Product to
the extent separately invoiced and included in the gross sales price; and (f) an
allowance for uncollectible or bad debts for such Product determined in
accordance with generally accepted accounting principles not to exceed 3% of Net
Sales of such Product for the applicable quarterly reporting period before
giving effect to this subsection (f).

 

 2 

 

 

1.12 “Payment Period” means, on a Product-by-Product and country-by-country
basis, the period of time equal to the longer of (a) beginning on the date of
the First Commercial Sale of such Product in such country and continuing during
the term for which a Valid Claim (if such Valid Claim were in an issued patent)
in such country remains in effect and would be infringed (if such Valid Claim
were in an issued patent not owned by or licensed to Harrow) by the manufacture,
use, offer for sale, sale or import of such Product in such country; and (b)
fifteen (15) years following the date of the First Commercial Sale of such
Product in such country.

 

1.13 “Person” means any individual, partnership, firm, corporation, association,
trust, unincorporated organization or other entity, as well as any syndicate or
group of any of the foregoing.

 

1.14 “Product” means any product, in any form or formulation for injectable
administration, comprising synthetic corticotropin.

 

1.15 “Product Supported Patent Rights” means, collectively, (a) all patent
applications filed anywhere in the world after May 9, 2017; (b) all patents that
have issued or in the future issue from any of the foregoing patent
applications, including without limitation utility models, design patents and
certificates of invention; and (c) all divisionals, continuations,
continuations-in-part, reissues, renewals, extensions or additions to any such
patents and patent applications; in each case that use or are supported by data
and information derived from the development, manufacture or use of the Product
or otherwise from the exploitation of the Technology; provided, however, that
Product Supported Patent Rights shall exclude the Assigned Patent Rights.

 

1.16 “Regulatory Approval” means, with respect to a particular country or
regulatory jurisdiction, any and all approvals, clearances or other
authorizations to develop, test, use, make, transport, store or commercialize a
particular product or service in such country or regulatory jurisdiction,
including all amendments and supplements thereto.

 

1.17 “Regulatory Authority” means any national, supra national, regional, state
or local regulatory authority, department, bureau, commission, council or other
governmental authority (including the FDA) that is responsible for overseeing
the development, testing, use, making, transport, storage or commercialization
of a product or service.

 

1.18 “Regulatory Filings” means, with respect to a particular country or
regulatory jurisdiction, any and all applications for, notifications or other
submissions made to or with a Regulatory Authority that is necessary or
reasonably desirable to develop, test, use, make, transport, store or
commercialize a particular product or service in such country or regulatory
jurisdiction, whether made before or after receipt of approval, clearance or
other authorization in such country or regulatory jurisdiction, including all
amendments and supplements thereto.

 

1.19 “Tax” or “Taxes” means any and all federal, state, local and foreign taxes,
assessments and other governmental charges, duties, impositions and liabilities,
including taxes based upon or measured by gross receipts, income, profits,
sales, use and occupation, and value added, ad valorem, transfer, franchise,
withholding, payroll, recapture, employment, excise and property taxes as well
as public imposts, fees and social security charges (including but not limited
to health, unemployment and pension insurance), together with all interest,
penalties and additions imposed with respect to such amounts and any obligation
under any agreement or arrangement with any other Person with respect to such
amounts and including any liability for taxes of a predecessor entity.

 

 3 

 

 

1.20 “Technology” means the Product together with any and all uses and methods
of manufacture thereof.

 

1.21 “Third Party” means any Person other than Harrow, Eton or their respective
Affiliates.

 

1.22 “Valid Claim” means either (a) a claim of an issued and unexpired patent
included within the Assigned Patent Rights, which has not been held permanently
revoked, unenforceable or invalid by a decision of a court or other governmental
agency of competent jurisdiction, unappealable or unappealed within the time
allowed for appeal, and which has not been admitted to be invalid or
unenforceable through reissue or disclaimer or otherwise, or (b) a claim of a
pending patent application included within the Assigned Patent Rights, which
claim was filed in good faith and has not been abandoned or finally disallowed
without the possibility of appeal or refiling of such application.

 

2. Purchase and Sale of the Assets.

 

2.1 Assets. Subject to the terms and conditions of this Agreement, Harrow hereby
agrees to, and hereby does, purchase from Eton, and Eton hereby agrees to, and
hereby does, sell, convey, transfer and assign to Harrow, on the Effective Date,
all of Eton’s right, title and interest in and to the Assets, including without
limitation all those assets described on Schedule 1 of the Patent Assignment
attached hereto as Exhibit A. Concurrently with the execution of this Agreement,
Eton shall deliver all required consents to Material Contracts (as defined
below) as set forth on Schedule 4.7 hereof. To the extent necessary to comply
with applicable privacy laws, Eton shall have the right to redact patient
identifying information from any data or information transferred to Harrow.

 

2.2 No Assumption of Liabilities. Harrow shall not be obligated to assume or
perform and is not assuming or performing any liabilities or obligations of Eton
which relate to Eton’s ownership of the Assets prior to the Effective Date or
otherwise, whether known or unknown, fixed or contingent, certain or uncertain,
and regardless of when they are or were asserted, and Eton shall remain
responsible for and shall promptly pay such liabilities.

 

2.3 Transfer Documents. The sale, conveyance, transfer and assignment of the
Assets may be further evidenced by the due execution and delivery by the parties
of any additional bills of sale, assignment or other title transfer documents
and instruments as reasonably requested by Harrow. Without limiting the
generality of the foregoing, (a) on the Effective Date, Eton shall duly execute
and deliver to Harrow the patent assignment in the form attached as Exhibit A
(the “Patent Assignment”) evidencing the sale, conveyance, transfer and
assignment of the Assigned Patent Rights from Eton to Harrow in accordance with
this Agreement, and (b) at such time as reasonably requested by Harrow on or
after the Effective Date, Eton shall duly execute and deliver to Harrow such
additional bills of sale, assignment or other title transfer documents and
instruments as reasonably requested by Harrow evidencing the sale, conveyance,
transfer and assignment of the Assets in accordance with this Agreement.

 

 4 

 

 

2.4 Consideration. The consideration for the sale to Harrow of the Assets under
this Agreement shall consist of the following (collectively, the “Purchase
Price”): the Payment Amount (as defined below) and the Milestone Payments (as
defined below).

 

2.5 Allocation of Purchase Price. The Purchase Price shall be allocated, if an
allocation is required, by Harrow within sixty (60) days following a
determination that such allocation is required. After the Effective Date, Harrow
and Eton shall make consistent use of any allocation required under Section 1060
of the Internal Revenue Code for all Tax purposes and in all filings,
declarations and reports with the Internal Revenue Service or any other
applicable taxing authority in respect thereof. In any and all actions, suits,
proceedings, arbitration, or governmental or regulatory investigations or audits
related to the determination of any Tax, neither Harrow nor Eton shall contend
or represent that such allocation is not a correct allocation.

 

3. License Grant.

 

3.1 License to Harrow. Eton hereby grants to Harrow a non-exclusive,
irrevocable, perpetual, non-transferable (except in connection with a permitted
assignment of this Agreement), worldwide license under the Product Supported
Patent Rights for all uses. Harrow shall have the right to grant sublicenses
under the Product Supported Patent Rights, through multiple tiers, to Third
Parties and Affiliates.

 

3.2 No Implied Licenses. Only licenses and rights expressly granted herein shall
be of legal force and effect. No license or other right shall be created
hereunder by implication, estoppel, or otherwise.

 

4. Representations and Warranties of Eton. Eton hereby represents and warrants
to Harrow, except as indicated on the disclosure schedules, if any, attached to
this Agreement, as follows:

 

4.1 Authority and Binding Effect. Eton has the full power and authority to
execute and deliver this Agreement, the Patent Assignment and other documents
and instruments contemplated hereby. This Agreement, the Patent Assignment and
other documents and instruments contemplated hereby, and the consummation by
Eton of its obligations contained herein and therein, have been duly authorized
by all necessary actions of Eton, and this Agreement, the Patent Assignment and
other documents and instruments contemplated hereby have been duly executed and
delivered by Eton. This Agreement, the Patent Assignment and other documents and
instruments contemplated hereby are valid and binding agreements of Eton,
enforceable against Eton in accordance with their respective terms.

 

 5 

 

 

4.2 Organization and Standing. Eton is duly organized, validly existing and in
good standing under the laws of the State of Delaware. Eton is qualified to do
business in each jurisdiction where such qualification is necessary. Eton has
the requisite corporate power and authority to conduct its business as now
conducted, to own the Assets and to use such Assets in the conduct of its
business.

 

4.3 Intellectual Property.

 

4.3.1 All Assigned Patent Rights as of the Effective Date are listed in Schedule
1 of the Patent Assignment attached hereto as Exhibit A.

 

4.3.2 Eton has good and marketable title to each of the Assets, and each of the
Assets is held or controlled by Eton free and clear of any Encumbrances
(including without limitation any distribution rights and royalty rights). All
Assets and will be fully transferable, alienable or licensable by Harrow without
restriction and without payment of any kind to any Third Party.

 

4.3.3 All Assets (including without limitation the Assigned Patent Rights) are
currently in compliance with applicable legal requirements (including payment of
filing, examination and maintenance fees and proofs of use), and are not subject
to any unpaid maintenance fees or taxes or actions falling due within ten (10)
days after the Effective Date.

 

4.3.4 To the extent that any Assets were originally owned or created by or for
any Person other than Eton, (a) Eton has obtained or will procure the complete,
unencumbered and unrestricted right to effect the transfer of the Assets from
Eton to Harrow and confirms that such transfer does not violate any such right
to transfer; (b) no Third Parties have retained or otherwise have any rights or
licenses with respect to the Assets; and (c) to the Knowledge of Eton, no valid
basis exists for any such Person to challenge or object to this Agreement or the
transactions contemplated herein.

 

4.3.5 Eton has not transferred ownership of, or granted any license of or right
to use, or authorized the retention of any rights to use, to any Person any
Assets.

 

4.3.6 To Eton’s Knowledge, Eton is not required to make or accrue any royalty,
milestone or other similar payment to any Third Party in connection with any of
the Assets.

 

4.3.7 To Eton’s Knowledge, none of the Assets transferred hereunder infringe
upon or misappropriate the intellectual property of any Third Party.

 

4.4 Conflicts; Consents. The execution and delivery by Eton of this Agreement
and the Patent Assignment, and the consummation of the transactions contemplated
hereby, will not conflict with (a) any provision of the certificate of
incorporation or bylaws of Eton, each as amended to date; (b) Contracts to which
Eton or any of its properties or assets (including intangible assets) is
subject; or (c) any judgment, order, decree, statute, law, ordinance, rule or
regulation applicable to Eton or any of its properties or assets (tangible and
intangible). It is not necessary for Eton to take any action or to obtain any
approval, consent or release by or from any Third Party, governmental or other,
to enable Eton to enter into or perform its obligations under this Agreement and
the Patent Assignment.

 

 6 

 

 

4.5 Litigation and Proceedings. There is no claim, action, suit, proceeding or
investigation (or any counter or cross-claim in an action brought by or on
behalf of Eton), whether at law or in equity, or before or by any governmental
department, commission, board, bureau, agency or instrumentality, domestic or
foreign, or before any arbitrator of any kind, that is pending or, to Eton’s
Knowledge, threatened, against Eton, which (i) could reasonably be expected to
adversely affect Eton’s ability to perform its obligations under this Agreement
or the Patent Assignment or complete any of the transactions contemplated
hereby; or (ii) involves the possibility of any judgment or liability, or which
may become a claim, against the Assets, Harrow or its business. Eton is not
subject to any judgment, order, writ, injunction, decree or award of any court,
arbitrator or governmental department, commission, board, bureau, agency or
instrumentality having jurisdiction over Eton or any of the Assets that affects,
involves or relates to the Assets.

 

4.6 Compliance with Law/Permits. Eton is in compliance with all, and is not in
violation of any, law, ordinance, order, decree, rule or regulation of any
governmental agency or authority, the violation of or noncompliance with which
could have a material adverse effect on Eton. No unresolved (a) charges of
violations of laws or regulations relating to Eton’s business have been made or
threatened; (b) proceedings or investigations relating to Eton’s business are
pending or have been threatened; and (c) citations or notices of deficiency have
been issued or have been threatened, against Eton relating to or arising out of
its business by any governmental authorities.

 

4.7 Contracts. Schedule 4.7 lists the Contracts to which Eton is a party as of
the date hereof which arise out of or relate to the Assets by which any of the
Assets are currently bound (the “Material Contracts”). Eton is not in violation
of or in default under (nor is there existing conditions which with either the
passage of time or giving of notice or both would cause such a violation or
default under) any such Material Contract. Each such Material Contract is in
full force and effect, and has a legal, valid and binding obligation on Eton,
and to Knowledge of Eton, each of the other parties thereto, and is enforceable
in accordance with its terms. Eton has not received notice that it is in
violation or breach of or in default under any such Material Contract. Except as
set forth on Schedule 4.7, no such Material Contract has a provision that would
require consent, notice or the payment of money or transfer of property as a
result of the transactions contemplated herein.

 

4.8 Full Disclosure. The representations and warranties made by Eton in this
Agreement and the schedules to be delivered pursuant to this Agreement do not
contain any untrue statement of material fact or omit to state a material fact
necessary to make any of them in the light of the circumstances in which they
were made, not misleading.

 

4.9 No Broker. Eton has not retained or used the services of an agent, finder,
or broker in connection with the transactions contemplated by this Agreement

 

5. Representations and Warranties of Harrow. Harrow represents and warrants to
Eton as follows:

 

5.1 Authority and Binding Effect. Harrow has the full corporate power and
authority to execute and deliver this Agreement and the Patent Assignment. This
Agreement and the Patent Assignment, and the consummation by Harrow of its
obligations contained herein and therein, have been duly authorized by all
necessary corporate actions of Harrow, and this Agreement and the Patent
Assignment have been duly executed and delivered by Harrow. This Agreement and
the Patent Assignment are valid and binding agreements of Harrow, enforceable
against Harrow in accordance with their respective terms.

 

 7 

 

 

5.2 Organization and Standing. Harrow is a corporation duly organized, validly
existing and in good standing under the laws of the State of Delaware, and
Harrow is qualified to do business in each jurisdiction where such qualification
is necessary and where the failure to be so qualified would have a material
adverse effect on Harrow. Harrow has the requisite corporate power and authority
to conduct its business as now conducted.

 

5.3 Conflicts; Consents. The execution and delivery by Harrow of this Agreement
and the Patent Assignment, and the consummation of the transactions contemplated
hereby, will not give rise to a conflict with respect to (a) any provision of
the certificate of incorporation or bylaws of Harrow, each as amended to date;
(b) Contracts to which Harrow or any of its properties or assets (including
intangible assets) is subject; or (c) any judgment, order, decree, statute, law,
ordinance, rule or regulation applicable to Harrow or any of its properties or
assets (tangible and intangible), except in any such case where it would not
have a material adverse effect on Eton’s rights under the Assets. It is not
necessary for Harrow to take any action or to obtain any approval, consent, or
release by or from any Third Party, governmental or other, to enable Harrow to
enter into or perform its obligations under this Agreement and the Patent
Assignment.

 

5.4 Compliance with Law/Permits. Harrow is in compliance with all, and is not in
violation of any, law, ordinance, order, decree, rule or regulation of any
governmental agency or authority, the violation of or noncompliance with which
could have a material adverse effect on Harrow. No unresolved (a) charges of
violations of laws or regulations relating to Harrow’s business have been made
or threatened; (b) proceedings or investigations relating to Harrow’s business
are pending or have been threatened; and (c) citations or notices of deficiency
have been issued or have been threatened, against Harrow relating to or arising
out of its business by any governmental authorities, which have had or could
reasonably be expected to have, individually or in the aggregate, a material
adverse effect on Harrow.

 

5.5 No Broker. Harrow has not retained or used the services of an agent, finder,
or broker in connection with the transactions contemplated by this Agreement.

 

6. Financial Terms.

 

6.1 Milestone Payments. Within seventy-five (75) days following the first
achievement of each milestone event set forth below by Harrow, a Licensee, or
one of their respective Affiliates, Harrow shall provide Eton with written
notice thereof and shall pay to Eton the corresponding one-time milestone
payment (each a “Milestone Payment”):

 

Milestone Event   Milestone Payment [* * *]   [* * *] [* * *]   [* * *] [* * *]
  [* * *]

 

 8 

 

 

6.2 Net Sales Payment Amounts.

 

6.2.1 Net Sales Payment Consideration. Subject to the provisions in this Section
6.2, on a Product-by-Product and country-by-country basis, Harrow shall pay to
Eton, on a quarterly basis, [* * *] of Net Sales of any Product during the
applicable Payment Period (the “Payment Amount”); provided, however, if the
manufacture, use, offer for sale, sale, or import of such Product in a
particular country would not infringe a Valid Claim (if such Valid Claim were in
an issued patent and not owned by or licensed to Harrow), then the applicable
Payment Amount with respect to such Product in such country shall be reduced by
one-half (½).

 

6.2.2 Combination/Bundled Products. In the event that a Product is sold by
Harrow, its Licensees or their respective Affiliates in combination with one or
more products which is itself not a Product, then Net Sales shall be calculated
by multiplying the sales price of such combination sale by the fraction A/(A+B)
where A is the fair market value of the Product(s) and B is the fair market
value of the other product(s) in the combination sale, each as reasonably
determined by Harrow.

 

6.3 Reports and Net Sales Payments. Within seventy-five (75) days after the end
of each calendar quarter during the applicable Payment Period, Harrow shall
deliver to Eton a report setting forth for such calendar quarter (a) the
calculation of the applicable Payment Amount; (b) the payments due under this
Agreement for the sale of each Product; and (c) the applicable exchange rate as
determined below. Harrow shall remit the total payments due for the sale of
Products during such calendar quarter at the time such report is made. No such
reports or payments shall be due for any Product prior to the First Commercial
Sale of such Product. With respect to Net Sales received in United States
dollars, all amounts shall be expressed in United States dollars. With respect
to Net Sales received in a currency other than United States dollars, all
amounts shall be expressed both in the currency in which the amount is invoiced
(or received as applicable) and in the United States dollar equivalent. The
United States dollar equivalent shall be calculated using the average of the
exchange rate (local currency per US$1) published in The Wall Street Journal,
Western Edition, under the heading “Currency Trading” on the last business day
of each month during the applicable calendar quarter.

 

6.4 Payment Provisions.

 

6.4.1 Payment Terms. The Payment Amount shown to have accrued by each report
provided for under Section 6.3 shall be due on the date such report is due.
Payment of the Payment Amount in whole or in part may be made in advance of such
due date.

 

6.4.2 Exchange Control. If at any time legal restrictions prevent the prompt
remittance of part or all Payment Amount with respect to any country in where a
Product is sold, Harrow shall have the right, in its sole discretion, to make
such payments by depositing the amount thereof in local currency to Eton’s
account in a bank or other depository institution in such country. If the
payment rate specified in this Agreement should exceed the permissible rate
established in any country, the payment rate for sales in such country shall be
adjusted to the highest legally permissible or government-approved rate.

 

 9 

 

 

6.4.3 Withholding Taxes. Harrow shall be entitled to deduct the amount of any
withholding taxes, value-added taxes or other taxes, levies or charges with
respect to such amounts, other than United States taxes, payable by Harrow, its
Licensees or its or their respective Affiliates, or any taxes required to be
withheld by Harrow, its Licensees or its or their respective Affiliates, to the
extent Harrow, its Licensees or their respective Affiliates pay to the
appropriate governmental authority on behalf of Eton such taxes, levies or
charges. Harrow shall use reasonable efforts to minimize any such taxes, levies
or charges required to be withheld on behalf of Eton by Harrow, its Licensees or
its or their respective Affiliates. Harrow promptly shall deliver to Eton proof
of payment of all such taxes, levies and other charges, together with copies of
all communications from or with such governmental authority with respect
thereto.

 

6.5 Audits. Upon the written request of Eton and not more than once in each
calendar year, Harrow shall permit an independent certified public accounting
firm of nationally recognized standing selected by Eton and reasonably
acceptable to Harrow, at Eton’s expense, to have access during normal business
hours to such of the financial records of Harrow as may be reasonably necessary
to verify the accuracy of the Payment Amount reports hereunder for the eight (8)
calendar quarters immediately prior to the date of such request (other than
records for which Eton has already conducted an audit under this Section). If
such accounting firm concludes that additional amounts were owed during the
audited period, Harrow shall pay such additional amounts within thirty (30) days
after the date Eton delivers to Harrow such accounting firm’s written report so
concluding. The fees charged by such accounting firm shall be paid by Eton;
provided, however, if the audit discloses that the Payment Amount payable by
Harrow for such period are more than one hundred ten percent (110%) of the
Payment Amount actually paid for such period, then Harrow shall pay the
reasonable fees and expenses charged by such accounting firm. Eton shall cause
its accounting firm to retain all financial information subject to review under
this Section 6.5 in strict confidence; provided, however, that Harrow shall have
the right to require that such accounting firm, prior to conducting such audit,
enter into an appropriate non-disclosure agreement with Harrow regarding such
financial information. The accounting firm shall disclose to Eton only whether
the reports are correct or not and the amount of any discrepancy. No other
information shall be shared. Eton shall treat all such financial information as
Harrow’s confidential information, and shall not disclose such financial
information to any Third Party or use it for any purpose other than as specified
in this Section 6.5.

 

6.6 Survival. This Section 6 shall survive the expiration or termination of this
Agreement and shall only terminate upon the expiration of the Payment Period and
all payment obligations.

 

 10 

 

 

7. Post-Effective Date Covenants.

 

7.1 Harrow Diligence.

 

7.1.1 Harrow shall use commercially reasonable efforts (whether alone or with or
through its Licensees and its or their respective Affiliates) to research,
develop and commercialize a Product.

 

7.1.2 Harrow shall control, at its sole expense, the preparation, filing,
prosecution, maintenance and enforcement of the Assigned Patent Rights
consistent with prudent business practices and shall consider in good faith the
interests of Eton.

 

7.2 Eton Covenants.

 

7.2.1 Within thirty (30) days after the Effective Date, Eton shall transfer to
Harrow all Assets, including without limitation all items described on Exhibit
B.

 

7.2.2 For a period of twelve (12) months following the Effective Date, Eton
shall, and shall cause its Affiliates and its and their respective employees and
contractors to, respond to inquiries from Harrow and provide Harrow with such
technical assistance as reasonably requested regarding the Technology and other
Assets, including without limitation regarding the research, development,
manufacture, Regulatory Approval and commercialization of one or more Products,
and the preparation, filing, prosecution, maintenance and enforcement of patent
and other intellectual property rights relating thereto. Harrow shall pay to
Eton its documented reasonable out-of-pocket costs of providing such technical
assistance.

 

7.3 Further Assistance.

 

7.3.1 Eton shall provide all cooperation reasonably requested by Harrow in
connection with any effort by Harrow to establish, perfect, defend, or enforce
its rights in or to the Assets (including without limitation the Assigned Patent
Rights). Such cooperation shall include, without limitation, (a) executing such
further assignments, transfers, licenses, releases and consents, and (b)
providing such data and information, consulting with Harrow and executing and
delivering all such further documents and instruments, in each case as requested
by Harrow regarding the Assets (including without limitation the Assigned Patent
Rights).

 

7.3.2 To the extent Eton cannot transfer and assign any of the Assigned Patent
Rights, or any portion thereof, as of the Effective Date, then Eton shall assign
and transfer the same at the first opportunity to do so. To the extent further
transfer or assignment of any patents rights is required and Eton has not,
within fifteen (15) days after the delivery of such assignment to Eton, (a)
executed and returned to Harrow the form of assignment reasonably requested by
Harrow, or (b) delivered to Harrow a written objection to Harrow’s request, then
Eton hereby irrevocably appoints Harrow as its attorney-in-fact with the right,
authority, and ability to execute and enter into such assignment on behalf of
Eton. Eton stipulates and agrees that such appointment is a right coupled with
an interest and shall survive the incapacity or unavailability of Eton at any
future time. To the extent that any of the Assigned Patent Rights cannot be
assigned and transferred by Eton, then Eton hereby grants Harrow an irrevocable,
worldwide, fully-paid up, royalty-free, exclusive license, with the right to
sublicense through multiple tiers, under the Assigned Patent Rights for all
purposes.

 

 11 

 

 

7.3.3 Eton shall provide all cooperation reasonably requested by Harrow, and
shall provide all technical assistance and to support reasonably requested by
Harrow, regarding (a) the exploitation of the Technology (including without
limitation the research, development and production of any Product), and (b)
applying for, obtaining and maintaining any and all approvals, licenses,
registrations or authorizations necessary or desirable to test, market or
commercialize the Technology (including without limitation any Product). Such
cooperation shall include, without limitation, providing such data and
information, consulting with Harrow and executing and delivering all such
further documents and instruments, in each case as requested by Harrow regarding
the Technology.

 

7.3.4 Harrow shall own, and Eton hereby assigns to Harrow, all right title and
interest in and to all results and other work product resulting from the
activities described in this Section 7.3, together with all patent rights and
other intellectual property rights therein and thereto.

 

8. Indemnification.

 

8.1 Indemnification by Eton. Subject to the provisions of this Section 8, Eton
shall indemnify, defend and hold harmless Harrow, its officers, directors,
affiliates, agents, stockholders and representatives (collectively, the “Harrow
Indemnitees”), from and against any and all losses, liabilities, damages and
expenses (including without limitation reasonable expenses of investigation and
attorneys’ and consultants’ fees and expenses in connection with any claim,
demand, action or proceeding or settlement of any of any of the foregoing)
(collectively, “Losses”) incurred or suffered by an Harrow Indemnitee to the
extent arising out of:

 

8.1.1 any breach of the representations and warranties of Eton set forth in this
Agreement;

 

8.1.2 any breach of any covenant or agreement of Eton set forth in this
Agreement or in any certificate, instrument, or other document delivered
pursuant to this Agreement; and

 

8.1.3 the ownership or operation of the Assets prior to the Effective Date or
any liability or obligation whatsoever of Eton.

 

8.2 Indemnification by Harrow. Subject to the provisions of this Section 8,
Harrow shall indemnify and hold harmless Eton, its officers, directors,
affiliates, agents, stockholders and representatives (collectively, the “Eton
Indemnitees”), from and against any and all Losses incurred or suffered by a
Eton Indemnitee to the extent arising out of:

 

8.2.1 any breach of the representations and warranties of Harrow set forth in
this Agreement;

 

 12 

 

 

8.2.2 any breach of any covenant or agreement of Harrow set forth in this
Agreement or in any certificate, instrument, or other document delivered
pursuant to this Agreement;

 

8.2.3 the ownership or operation of the Assets after the Effective Date or the
manufacture, use, or sale of Product solely by Harrow, its Licensees or their
respective Affiliates or use of Product by their customers.

 

8.3 Offset. Harrow may offset against the Payment Amount or any other amounts
due Eton from Harrow, any amounts owed to Harrow for indemnification under
Section 8.1. The exercise of such offset by Harrow in good faith, whether or not
ultimately determined to be justified, shall not constitute an event of default
hereunder. Neither the exercise nor the failure to exercise, any such right of
offset shall constitute an election of remedies or limit Harrow in any manner in
the enforcement of any other remedies that may be available to it.

 

8.4 Procedure. A party seeking indemnification (the “Indemnitee”) shall promptly
notify the other party (the “Indemnifying Party”) in writing of a claim or suit;
provided that an Indemnitee’s failure to give such notice or delay in giving
such notice shall not affect such Indemnitee’s right to indemnification under
this Section 8 except to the extent that the Indemnifying Party has been
prejudiced by such failure or delay. Harrow shall have the right to control the
defense of all indemnification claims hereunder. Eton shall have the right to
participate at its own expense in the claim or suit with counsel of its own
choosing. Harrow shall consult with the Indemnitee in good faith with respect to
all non-privileged aspects of the defense strategy. Eton shall cooperate with
Harrow as reasonably requested, at Eton’s sole cost and expense. Harrow shall
not settle any claim or suit with respect to which Eton is the Indemnifying
Party without Eton’s prior written consent, which consent shall not be
unreasonably withheld.

 

9. Confidentiality.

 

9.1 Confidential Information. During the term of this Agreement, and for a
period of five (5) years following the expiration or earlier termination hereof,
except as otherwise provided in this Section 9, Eton shall maintain in
confidence all data and information comprising the Assets (the “Confidential
Information”), and shall not use, disclose or grant the use of the Confidential
Information except on a need-to-know basis to those directors, officers,
employees and contractors, to the extent such disclosure is reasonably necessary
in connection with performing its obligations or exercising its rights under
this Agreement. To the extent that disclosure is authorized by this Agreement,
prior to disclosure, Eton shall obtain agreement of any such Person to hold in
confidence and not make use of the Confidential Information for any purpose
other than those permitted by this Agreement. Eton shall notify the other
promptly upon discovery of any unauthorized use or disclosure of the
Confidential Information.

 

9.2 Terms of this Agreement. Except as otherwise provided in this Section 9,
neither party shall disclose any terms or conditions of this Agreement to any
Third Party without the prior consent of the other party; provided, however,
that a party may disclose the terms or conditions of this Agreement, (a) on a
need-to-know basis to its legal and financial advisors to the extent such
disclosure is reasonably necessary, and (b) to a Third Party in connection with
(i) an equity investment in such party, (ii) a merger, consolidation or similar
transaction by such party, (iii) a permitted (sub)license under this Agreement,
or (iv) the sale of all or substantially all of the assets of such party.
Notwithstanding the foregoing, prior to execution of this Agreement, the parties
have agreed upon the substance of information that can be used to describe the
terms of this transaction, and each party may disclose such information, as
modified by mutual agreement from time to time, without the other party’s
consent.

 

 13 

 

 

9.3 Permitted Disclosures. The confidentiality obligations contained in this
Section 9 shall not apply to the extent that (a) a party is required (i) in the
reasonable opinion of such party’s legal counsel, to disclose information by
applicable law, regulation, rule (including rule of a stock exchange or
automated quotation system), order of a governmental agency or a court of
competent jurisdiction or legal process, including tax authorities, or (ii) to
disclose information to any governmental agency for purposes of obtaining
approval to test or market a product, provided in either case that, to the
extent practicable, such party shall provide written notice thereof to the other
party and sufficient opportunity to object to any such disclosure or to request
confidential treatment thereof; or (b) a party can demonstrate that (i) the
information was or became public knowledge, other than as a result of actions of
such party in violation hereof; or (ii) the information was disclosed to the
recipient on an unrestricted basis from a source unrelated to any party to this
Agreement and not under a duty of confidentiality to the other party.
Notwithstanding anything to the contrary herein, Harrow may disclose the terms
and conditions of this Agreement to any Person with whom Harrow has, or is
proposing to enter into, a business relationship, as long as such Person has
entered into a confidentiality agreement with Harrow.

 

9.4 Injunctive Relief. Each party acknowledges that it will be impossible to
measure in money the damage to the other party if such party fails to comply
with the obligations imposed by this Section 9, and that, in the event of any
such failure, the other party may not have an adequate remedy at law or in
damages. Accordingly, each party agrees that injunctive relief or other
equitable remedy, in addition to remedies at law or damages, is an appropriate
remedy for any such failure and shall not oppose the granting of such relief on
the basis that the disclosing party has an adequate remedy at law. Each party
agrees that it shall not seek, and agrees to waive any requirement for, the
securing or posting of a bond in connection with the other party seeking or
obtaining such equitable relief.

 

10. Term. The term of this Agreement shall continue until expiration of all
payment obligations hereunder.

 

11. Miscellaneous.

 

11.1 Termination of Original Agreement. The parties hereby terminate the
Original Agreement in its entirety (including without limitation Section 9.2,
which shall not apply), provided, however, that Section 5.4 shall remain in full
force and effect.

 

11.2 Assignment. Neither party shall assign its rights or obligations under this
Agreement without the prior written consent of the other party; provided,
however, that a party may, without such consent, assign this Agreement and its
rights and obligations hereunder (a) to any Affiliate, or (b) in connection with
the transfer or sale of all or substantially all of its business to which this
Agreement relates, or in the event of its merger, consolidation, change in
control or similar transaction. Any permitted assignee shall assume all
obligations of its assignor under this Agreement. Any purported assignment in
violation of this Section 11.2 shall be void.

 

 14 

 

 

11.3 Severability. Any provision of this Agreement which is illegal, invalid or
unenforceable shall be ineffective to the extent of such illegality, invalidity
or unenforceability, without affecting in any way the remaining provisions
hereof.

 

11.4 Governing Law; Exclusive Jurisdiction. This Agreement shall be governed by
and construed in accordance with the laws of the State of California, without
regard to the conflicts of law principles thereof. Each of the parties hereto
irrevocably consents to the exclusive jurisdiction and venue of any federal
court located in the Southern District of the State of California or state court
in San Diego, California having jurisdiction, in connection with any matter
based upon or arising out of this Agreement or the matters contemplated herein,
agrees that process may be served upon them in any manner authorized by laws of
the State of California for such persons and waives and covenants not to assert
or plead any objection which they might otherwise have to such jurisdiction,
venue and such process.

 

11.5 Entire Agreement; Amendment. This Agreement, together with the Exhibits
hereto, and each additional document, instrument or other agreement to be
executed and delivered pursuant hereto constitute all of the agreements of the
parties with respect to, and supersede all prior agreements and understandings
relating to the subject matter of, this Agreement or the transactions
contemplated by this Agreement. This Agreement may not be modified or amended
except by a written instrument specifically referring to this Agreement signed
by the parties hereto.

 

11.6 Waiver. No waiver by one party of the other party’s obligations, or of any
breach or default hereunder by any other party, shall be valid or effective,
unless such waiver is set forth in writing and is signed by the party giving
such waiver; and no such waiver shall be deemed a waiver of any subsequent
breach or default of the same or similar nature or any other breach or default
by such other party.

 

11.7 Notices. Any consent, notice or report required or permitted to be given or
made under this Agreement by a party to the other party shall be in writing,
delivered by any lawful means to such other party at its address indicated
below, or to such other address as the addressee shall have last furnished in
writing to the addressor and (except as otherwise provided in this Agreement)
shall be effective upon receipt by the addressee.

 

If to Eton: Eton Pharmaceuticals, Inc.   21925 W. Field Pkwy, Suite 235   Deer
Park, Illinois 60010   Attention: Chief Executive Officer     If to Harrow:
Harrow Health, Inc.   12264 El Camino Real, Suite 350   San Diego, California
92130   Attention: Chief Executive Officer

 

11.8 Counterparts. This Agreement may be executed in separate counterparts, each
of which shall be deemed an original, but all of which together shall constitute
one and the same instrument.

 

[SIGNATURE PAGE FOLLOWS.]

 

 15 

 

 

IN WITNESS WHEREOF, each party has caused a duly authorized representative to
execute and deliver this Asset Purchase Agreement as of the Effective Date.

 

Eton Pharmaceuticals, Inc.         By:                                Name:    
Title:           HARROW HEALTH, INC.         By:     Name:     Title:    

 

[Signature Page to Asset Purchase Agreement]

 

   

 

 

EXHIBIT A

 

PATENT ASSIGNMENT

 

WHEREAS, Eton Pharmaceuticals, Inc., a Delaware corporation (“Assignor”), with a
place of business at 21925 W. Field Parkway, Suite 235, Deer Park, Illinois
60010 is the owner of all rights, title, and interests in and to the patent
applications and patents shown on the attached Schedule 1 (the “Assigned Patent
Rights”); and

 

WHEREAS, HARROW HEALTH, INC., a Delaware corporation (“Assignee”), with a place
of business at 12264 El Camino Real, Suite 350, San Diego, California 92130,
desires to acquire the entire right, title, and interest in and to the Assigned
Patent Rights and all the inventions and discoveries disclosed and/or claimed in
the Assigned Patent Rights (the “Inventions”);

 

NOW THEREFORE, be it known that effective as of ___________, for good and
valuable consideration, the receipt and sufficiency of which are hereby
acknowledged, Assignor hereby sells, assigns, transfers, and sets over unto
Assignee (1) the entire right, title, and interest in all countries throughout
the world in and to said Assigned Patent Rights and Inventions, including any
renewals, revivals, reissues, reexaminations, extensions, continuations,
continuations-in-part, and divisions of said Assigned Patent Rights and any
substitute applications therefor; (2) the entire right to file patent
applications (“New Applications”) in the name of Assignee or its designee on the
aforesaid Inventions in all countries of the world; (3) the entire right, title,
and interest in and to any patent which issued and may issue on the Inventions
in any country, and any renewals, revivals, reissues, reexaminations, and
extensions thereof, and any patents of confirmation, registration, and
importation of the same; (4) the right to sue and recover for, and the right to
profits or damages due or accrued in connection with, any and all past, present,
or future infringements of the Assigned Patent Rights and Inventions; and (5)
the entire right, title, and interest in all convention and treaty rights of all
kinds, including without limitation all rights of priority in any country of the
world, in and to the above Assigned Patent Rights and Inventions.

 

AND for the same consideration, said Assignor hereby covenants and agrees to and
with said Assignee its successors, legal representatives and assigns, that, at
the time of execution and delivery of these presents, said Assignor is the sole
and lawful owner of the entire right, title and interest in and to said
Inventions and Assigned Patent Rights, and that the same are unencumbered and
that said Assignor has good and full right and lawful authority to sell and
convey the same in the manner herein set forth.

 

AND for the same consideration, said Assignor hereby covenants and agrees to and
with said Assignee, its successors, legal representatives and assigns, that said
Assignor will, whenever counsel of said Assignee, or the counsel of its
successors, legal representatives and assigns, shall advise that any proceeding
in connection with said Inventions and Assigned Patent Rights in any country,
including interference proceedings, is lawful and desirable, or that any
application for letters patent, or that any division, continuation or
continuation-in-part of any application for letters patent or any reissue or
extension of any letters patent, to be obtained thereon, is lawful and
desirable, sign all papers and documents, take all lawful oaths, and do all acts
necessary or required to be done for the procurement, maintenance, enforcement
and defense of said Inventions and Assigned Patent Rights, without charge to
said Assignee, its successors, legal representatives and assigns, but at the
cost and expense of said Assignee, its successors, legal representatives and
assigns.

 

 A-1 

 

 

AND, Assignor hereby authorizes and requests the competent authorities to grant
and to issue any and all patents on the Inventions throughout the world to
Assignee, its successors, or assigns, whose rights, title, and interests in such
patents are the same as would have been held and enjoyed by Assignor had this
assignment, sale, and transfer not been made.

 

IN WITNESS WHEREOF, the Assignor has caused this Patent Assignment to be duly
executed by its officer thereunto duly authorized as of the _____ day of _____,
2019.

 

  Eton Pharmaceuticals, Inc.       By:                                 Name:    
Title:  

 

STATE OF     )                   )             COUNTY OF     )  

 

On ____________________, before me, ____________________, a Notary Public,
personally appeared ____________________ who proved to me on the basis of
satisfactory evidence to be the person(s) whose name(s) is/are subscribed to the
within instrument and acknowledged to me that he/she/they executed the same in
his/her/their authorized capacity(ies), and that by his/her/their signature(s)
on the instrument the person(s), or the entity upon behalf of which the
person(s) acted, executed the instrument.

 

I certify under PENALTY OF PERJURY under the laws of _______ that the foregoing
paragraph is true and correct.

 

WITNESS my hand and official seal.

 

Signature _______________________________

 

  Acknowledgement of Assignee:       HARROW HEALTH, INC.         By:
                        Name:     Title:  

 

 A-2 

 

 

EXHIBIT A: SCHEDULE 1

 

ASSIGNED PATENT RIGHTS

 

[* * *]

 

 A-3 

 

 

EXHIBIT B

 

CERTAIN ASSETS TO BE TRANSFERRED

 

Copies of the following with respect to any Product (in each case, excluding any
individually identifiable health information):

 

  ● Product stability reports and records, including stability testing results  
● Compounding and packaging protocols and formulation documentation   ●
Acceptance criteria for analytical methods and specifications of end-product   ●
Records related to in-process control documentation, process validation and
cleaning validation   ● Quality control policies   ● Documentation related to
the source API and excipients, including Material Safety Data Sheets   ● Records
relating to pre-clinical studies   ● FDA correspondences and meeting minutes

 

 A-4